tm logo
RADICAVA ORS
Live/Registered
REGISTERED

on 22 Nov 2022

Last Applicant/ Owned by

Chuo-ku, Osaka-shi

Osaka

JP

541-8505

Serial Number

90594021 filed on 22nd Mar 2021

Registration Number

6908091 registered on 22nd Nov 2022

in the Principal Register

Correspondent Address

Jeffrey Costellia

NIXON PEABODY LLP

799 9TH STREET, NW, SUITE 500

WASHINGTON, DC 20001

Filing Basis

1. intent to use

2. use application currently

Disclaimer

NO DATA

RADICAVA ORS

Pharmaceutical preparations for the treatment of central nervous system diseases; pharmaceutical preparations for protection against free radicals; pharmaceutical preparations for removing free radicals from the human bodies; neuroprotective medicines; pharmaceutical preparations for the treatment of amyotrophic lateral sclerosis (ALS)

Classification Information


Class [005]
Pharmaceutical Products


Pharmaceutical preparations for the treatment of central nervous system diseases; pharmaceutical preparations for protection against free radicals; pharmaceutical preparations for removing free radicals from the human bodies; neuroprotective medicines; pharmaceutical preparations for the treatment of amyotrophic lateral sclerosis (ALS)


First Use Date in General

15th Jun 2022

First Use Date in Commerce

15th Jun 2022

Mark Details


Serial Number

No 90594021

Mark Type

No Service/Collective Mark

Attorney Docket Number

No 740630-234

44D Filed

No

44D Current

No

44E filed

No

44E Current

No

66A Filed

No

66A Current

No

Current Basis

No

No Basis

No

Legal History


Show more

Status DateAction Taken
22nd Nov 2022NOTICE OF REGISTRATION CONFIRMATION EMAILED
22nd Nov 2022REGISTERED-PRINCIPAL REGISTER
15th Oct 2022NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
14th Oct 2022ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
21st Sep 2022ASSIGNED TO EXAMINER
06th Aug 2022STATEMENT OF USE PROCESSING COMPLETE
06th Aug 2022CASE ASSIGNED TO INTENT TO USE PARALEGAL
20th Jul 2022USE AMENDMENT FILED
20th Jul 2022TEAS STATEMENT OF USE RECEIVED
25th Jan 2022NOA E-MAILED - SOU REQUIRED FROM APPLICANT